ABOLOGIX signs a license agreement with Research Development Foundation for two monoclonal antibodies for oncology

Jul 19, 2018
1 min read

Geneva, Switzerland, July 19, 2018 – Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche.

Abologix obtains funding from the KICK FUND

Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...

Successful completion of the Innosuisse Innovation Project

Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...

Nomination of product H225 as the lead preclinical candidate

Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...

ABOLOGIX signs a license agreement with Research Development Foundation for two monoclonal antibodies for oncology

Comments

Back to Top